Eli Lilly & Company (Lilly) is a global pharmaceutical company, developing therapies for various diseases.
Lilly was first company to mass-produce penicillin and was also, one of the first to produce human insulin using rDNA technology. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer.
- In Jan 2019, Lilly acquired Loxo Oncology, Inc., in approx. $8.0 billion USD. Loxo Oncology pipeline includes targeted medicines focused on cancers that are uniquely dependent on single gene abnormalities that can be detected by genomic testing.
- In May 2018, Lilly acquired ARMO BioSciences, Inc. (NASDAQ: ARMO) in approx. $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.
- In May 2018, Lilly acquired AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly, in up to $465 Mn USD. Earlier in 2016, Lilly sold the compound to TVM Capital Life Science, which then established AurKa as part of the TVM Life Science Ventures VII fund.
- In 2008, Lilly acquire SGX Pharmaceuticals Inc. for $64 Mn USD. SGX drug development program includes MET tyrosine kinase inhibitors and BCR-ABL tyrosine kinase enzyme for the treatment of CML.
- In Oct 2008, Lilly acquired ImClone Systems for $6.5 billion USD, currently operating as its wholly owned subsidiary.
- Lilly also acquired ICOS Corporation (developing Abs and small molecules for various diseases) in 2006 for $2.1 billion USD.
- In 2004, Lilly acquire Applied Molecular Evolution (AME) and make its wholly-owned subsidiary. AME focuses on protein therapeutic candidates including antibodies, cytokines, hormones and enzymes.
Page 1 of 3
